Acute lymphoblastic leukaemia (ALL) statistics

Cases

New cases of acute lymphoblastic leukaemia, 2015, UK

Deaths

Deaths from leukaemia, 2014, UK

 

  • There are around 810 new acute lymphoblastic leukaemia cases in the UK every year, that's more than 2 every day (2013-2015).
  • Acute lymphoblastic leukaemia is not among the 20 most common cancers in the UK, accounting for less than 1% of all new cancer cases (2015).
  • In males in the UK, acute lymphoblastic leukaemia is not among the 20 most common cancers, with around 460 new cases in 2015.
  • In females in the UK, acute lymphoblastic leukaemia is not among the 20 most common cancers, with around 370 new cases in 2015.
  • Incidence rates for acute lymphoblastic leukaemia in the UK are highest in people aged 0 to 04 (2013-2015).
  • Since the early 1990s, acute lymphoblastic leukaemia incidence rates have remained stable in the UK. Rates in males have remained stable, and rates in females have remained stable.
  • Over the last decade, acute lymphoblastic leukaemia incidence rates have remained stable in the UK. Rates in males have remained stable, and rates in females have remained stable.
  • 1 in 1,015 men and 1 in 1,340 women will be diagnosed with ALL during their lifetime.
  • Leukaemia (ALL) in England is less common in males living in the most deprived areas. There is no association for females.
  • An estimated 8,200 people who had previously been diagnosed with acute lymphoblastic leukaemia (ALL) were alive in the UK at the end of 2010.

See more in-depth ALL incidence statistics

  • There were around 240 acute lymphoblastic leukaemia (ALL) deaths in the UK in 2014, that’s around 5 deaths every week.
  • ALL accounts for less than 1% of all cancer deaths in the UK (2014).
  • In males in the UK, there were around 120 ALL deaths in 2014.
  • In females in the UK, there were around 120 ALL deaths in 2014.
  • Almost half (47%) of acute lymphoblastic leukaemia (ALL) deaths in the UK each year are in people aged 60 and over (2012-2014).
  • Mortality rates for ALL in the UK are highest in people aged 80-89 (2012-2014).
  • Since the early 1970s, acute lymphoblastic leukaemia (ALL) mortality rates have decreased by more than a half (53%) in the UK. The decrease is larger in males (58%), than in females (46%).
  • Over the last decade, ALL mortality rates have decreased by a quarter (25%) in the UK. The decrease in similar in males (27%) and females (22%).
  • Leukaemia (ALL) in England is not associated with deprivation.

See more in-depth ALL mortality statistics

  • Five-year relative survival for acute lymphoblastic leukaemia (ALL) in men is similar to the European average in England Wales and Scotland.
  • Five-year relative survival for acute lymphoblastic leukaemia (ALL) in women is similar to the European average in England, Wales, Scotland and Northern Ireland.

See more in-depth ALL survival statistics

  • ‘Two-week wait’ standards are met by all countries, and ‘31-day wait’ is met by all but England for acute leukaemia.

See more in-depth ALL diagnosis and treatment statistics

Want the key stats in the sections on this page as a document? or looking for a stats report of the in-depth stats? Use the print function at the bottom of any Cancer Stats page Share this page > Print or your browser options to print or save.

The latest incidence statistics available for acute lymphoblastic leukaemia (ALL) in the UK are; incidence 2015 and mortality 2014. Reliable survival data for the UK is currently not available.

The ICD code Open a glossary item for ALL is ICD-10 C91.0.

European Age-Standardised Rates were calculated using the 1976 European Standard Population (ESP) unless otherwise stated as calculated with ESP2013. ASRs calculated with ESP2013 are not comparable with ASRs calculated with ESP1976.

Lifetime risk estimates were calculated using incidence, mortality, population and all-cause mortality data for 2010-2012 due to the small number of cases.

Cancer waiting times statistics are for patients who entered the health care system within financial year 2014-15. AML is part of the group 'Acute leukaemia' for cancer waiting times data. Codes vary per country but broadly include: acute lymphoblastic, myeloid and monocytic leukaemia and some other leukaemia of specific or unspecified cell type.

Patient Experience data is for adult patients in England with a primary diagnosis of cancer, who were in active treatment between September and November 2013 and who completed a survey in 2014.

Deprivation gradient statistics were calculated using incidence data for three time periods: 1996-2000, 2001-2005 and 2006-2010 and for mortality for two time periods: 2002-2006 and 2007-2011. The 1997-2001 mortality data were only used for the all cancers combined group as this time period includes the change in coding from ICD-9 to ICD-10. The deprivation quintiles were calculated using the Income domain scores from the Index of Multiple Deprivation (IMD) from the following years: 2004, 2007 and 2010. Full details on the data and methodology can be found in the Cancer by Deprivation in England NCIN report.

See also

Data sources and timings - why are these the latest statistics?

Information and explanations on terminology used for statistics

Our calculations explained

Information for patients

Citation

You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:

Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.

When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, Angel Building, 407 St John Street, London, EC1V 4AD or

Donate online

Acknowledgements

We are grateful to the many organisations across the UK which collect, analyse, and share the data which we use, and to the patients and public who consent for their data to be used. Find out more about the sources which are essential for our statistics.

Rate this page:

Currently rated: 2.8 out of 5 based on 24 votes
Thank you!
We've recently made some changes to the site, tell us what you think

Share this page